-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 24, a total of 41 listed companies in the two A-share markets released their 2021 annual performance reports, including 4 in the pharmaceutical industry, namely Shanghai Yizhong, Warner Pharmaceuticals, Aibo Medical and Zejing Pharmaceuticals
.
Among the 4 pharmaceutical companies, 2 lost money and 2 reported good news
.
Shanghai Yizhong: Net loss of 3.
9971 million yuan in 2021 Shanghai Yizhong's 2021 annual performance bulletin shows that the total operating income in 2021 will be 4.
0775 million yuan; the net profit attributable to shareholders of the parent company is -3.
9971 million yuan, which is higher than the previous year.
Losses decreased during the same period
.
According to the report, the main factor affecting the operating performance is the approval of the company's core product, paclitaxel polymer micelles for injection, which has achieved sales performance in 2021
.
According to the data, Shanghai Yizhong is a high-tech pharmaceutical enterprise integrating R&D, production and sales.
It is committed to the R&D and industrialization of new improved anti-tumor drugs.
Its core product is paclitaxel polymer micelles for injection
.
Warner Pharmaceutical Factory: Net profit increased by 10.
33% year-on-year The performance report released by Warner Pharmaceutical Factory shows that in 2021, the company will obtain operating income of 1.
147 billion yuan, a year-on-year increase of 20.
61%; net profit attributable to the parent is 160 million yuan, a year-on-year increase of 10.
33%
.
During the reporting period, the company's sales continued to maintain growth, mainly from digestive products such as colloidal bismuth pectin preparations, anti-anemia products such as ferrous succinate tablets, anti-infective products such as fosfomycin tromethamine powder, and inhalation products.
Sales of respiratory products such as acetylcysteine solution and API products such as mycophenolate mofetil increased
.
Warner Pharmaceuticals is an enterprise whose main business is the research and development, production and sales of chemical raw materials, chemical preparations and traditional Chinese medicine preparations.
It has tablets, capsules, granules, powders, dry suspensions, inhalation solutions, small Volume injection, eye drops, freeze-dried powder injection and other dosage forms and production capacity of chemical raw materials
.
Aibo Medical: Net profit increased by 77.
45% year-on-year According to the announcement of Aibo Medical's 2021 annual performance report, the total operating income in 2021 will be 433 million yuan, an increase of 58.
61% over the same period last year; the net profit attributable to shareholders of the parent company is 171 million yuan, an increase of 77.
45% over the same period of the previous year
.
The increase in revenue was primarily attributable to the rapid growth in sales of the company's intraocular lenses and orthokeratology lenses
.
At the same time, in terms of orthokeratology lenses, with the decrease in the proportion of trial lenses, the average unit selling price of orthokeratology lenses has increased, making the revenue growth rate of orthokeratology lenses higher than the sales growth rate
.
It is reported that in 2021, the company's series of intraocular lenses such as "Pu Nuo Ming" will increase by 36.
37% year-on-year, and "Pu Nuo Tong" orthokeratology lenses will increase by 159.
54% year-on-year
.
Data show that Aibo Medical focuses on independent research and development of ophthalmic medical devices, Production, sales and related services, the company's products currently mainly include surgery and optometry, mainly for major ophthalmic diseases such as blindness and visual impairment caused by cataracts and refractive errors
.
Jing Pharmaceutical's 2021 annual performance bulletin shows that during the reporting period, the company achieved operating income of 201 million yuan, a year-on-year increase of 627.
04%, and the net profit attributable to owners of the parent company was -414 million yuan, an increase of 95.
2647 million yuan
in loss compared to the same period last year.
The company explained in the report that during the reporting period, the company's new drug research and development pipeline was further enriched, many innovative drugs were in the key clinical trial stage, and the research and development expenditure further increased.
At the same time, the company is in the pre-commercialization stage of drug listing and needs to invest a lot of pre-market expansion and academic promotion activities.
Therefore, the company has not yet achieved profitability
in 2021.
Zejing Pharmaceutical is a pharmaceutical company specializing in oncology, hemorrhage and blood diseases, An innovation-driven chemical and biological new drug research and development company in multiple therapeutic areas such as hepatobiliary diseases
.
.
Among the 4 pharmaceutical companies, 2 lost money and 2 reported good news
.
Shanghai Yizhong: Net loss of 3.
9971 million yuan in 2021 Shanghai Yizhong's 2021 annual performance bulletin shows that the total operating income in 2021 will be 4.
0775 million yuan; the net profit attributable to shareholders of the parent company is -3.
9971 million yuan, which is higher than the previous year.
Losses decreased during the same period
.
According to the report, the main factor affecting the operating performance is the approval of the company's core product, paclitaxel polymer micelles for injection, which has achieved sales performance in 2021
.
According to the data, Shanghai Yizhong is a high-tech pharmaceutical enterprise integrating R&D, production and sales.
It is committed to the R&D and industrialization of new improved anti-tumor drugs.
Its core product is paclitaxel polymer micelles for injection
.
Warner Pharmaceutical Factory: Net profit increased by 10.
33% year-on-year The performance report released by Warner Pharmaceutical Factory shows that in 2021, the company will obtain operating income of 1.
147 billion yuan, a year-on-year increase of 20.
61%; net profit attributable to the parent is 160 million yuan, a year-on-year increase of 10.
33%
.
During the reporting period, the company's sales continued to maintain growth, mainly from digestive products such as colloidal bismuth pectin preparations, anti-anemia products such as ferrous succinate tablets, anti-infective products such as fosfomycin tromethamine powder, and inhalation products.
Sales of respiratory products such as acetylcysteine solution and API products such as mycophenolate mofetil increased
.
Warner Pharmaceuticals is an enterprise whose main business is the research and development, production and sales of chemical raw materials, chemical preparations and traditional Chinese medicine preparations.
It has tablets, capsules, granules, powders, dry suspensions, inhalation solutions, small Volume injection, eye drops, freeze-dried powder injection and other dosage forms and production capacity of chemical raw materials
.
Aibo Medical: Net profit increased by 77.
45% year-on-year According to the announcement of Aibo Medical's 2021 annual performance report, the total operating income in 2021 will be 433 million yuan, an increase of 58.
61% over the same period last year; the net profit attributable to shareholders of the parent company is 171 million yuan, an increase of 77.
45% over the same period of the previous year
.
The increase in revenue was primarily attributable to the rapid growth in sales of the company's intraocular lenses and orthokeratology lenses
.
At the same time, in terms of orthokeratology lenses, with the decrease in the proportion of trial lenses, the average unit selling price of orthokeratology lenses has increased, making the revenue growth rate of orthokeratology lenses higher than the sales growth rate
.
It is reported that in 2021, the company's series of intraocular lenses such as "Pu Nuo Ming" will increase by 36.
37% year-on-year, and "Pu Nuo Tong" orthokeratology lenses will increase by 159.
54% year-on-year
.
Data show that Aibo Medical focuses on independent research and development of ophthalmic medical devices, Production, sales and related services, the company's products currently mainly include surgery and optometry, mainly for major ophthalmic diseases such as blindness and visual impairment caused by cataracts and refractive errors
.
Jing Pharmaceutical's 2021 annual performance bulletin shows that during the reporting period, the company achieved operating income of 201 million yuan, a year-on-year increase of 627.
04%, and the net profit attributable to owners of the parent company was -414 million yuan, an increase of 95.
2647 million yuan
in loss compared to the same period last year.
The company explained in the report that during the reporting period, the company's new drug research and development pipeline was further enriched, many innovative drugs were in the key clinical trial stage, and the research and development expenditure further increased.
At the same time, the company is in the pre-commercialization stage of drug listing and needs to invest a lot of pre-market expansion and academic promotion activities.
Therefore, the company has not yet achieved profitability
in 2021.
Zejing Pharmaceutical is a pharmaceutical company specializing in oncology, hemorrhage and blood diseases, An innovation-driven chemical and biological new drug research and development company in multiple therapeutic areas such as hepatobiliary diseases
.
